MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$10,181,000
Net Income
-$93,842,000
Net Profit Margin
-921.74%
EPS
-$0.94
Unit: Dollar
Revenue Breakdown
Collaboration Revenue
Grant
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total revenue
10,181,000
1,458,000
864,000
889,000
Research and development
67,152,000
68,574,000
83,526,000
58,902,000
Acquired in-process research and development
2,473,000
-
0
0
General and administrative
17,553,000
17,183,000
18,399,000
16,931,000
Collaboration expense, net
40,272,000
45,949,000
53,703,000
57,115,000
Total operating expenses
127,450,000
131,706,000
155,628,000
132,948,000
Loss from operations
-117,269,000
-130,248,000
-154,764,000
-132,059,000
Other income, net
27,075,000
8,156,000
24,765,000
26,237,000
Total other income, net
27,075,000
8,156,000
24,765,000
26,237,000
Net loss before income taxes
-90,194,000
-122,092,000
-129,999,000
-105,822,000
Provision for income taxes
960,000
839,000
614,000
619,000
Net loss
-91,154,000
-122,931,000
-130,613,000
-106,441,000
Foreign currency translation adjustment
6,000
-32,000
2,000
-28,000
Unrealized (gain) loss on marketable securities
-2,694,000
-6,730,000
-167,000
973,000
Comprehensive loss
-93,842,000
-129,693,000
-130,778,000
-105,496,000
Basic EPS
-0.94
-1.28
-1.371
-1.17
Diluted EPS
-0.94
-1.28
-1.371
-1.17
Basic Average Shares
96,514,102
96,051,228
95,386,689
91,305,337
Diluted Average Shares
96,514,102
96,051,228
95,386,689
91,305,337
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive loss
-$93,842,000
(55.02%↑ Y/Y)
Foreign currency
translation adjustment
$6,000
(-92.50%↓ Y/Y)
Net loss
-$91,154,000
(56.29%↑ Y/Y)
Unrealized (gain) loss on
marketable securities
-$2,694,000
(-1448.28%↓ Y/Y)
Other income, net
$27,075,000
(22.69%↑ Y/Y)
Net loss before
income taxes
-$90,194,000
(56.48%↑ Y/Y)
Provision for income taxes
$960,000
(-25.70%↓ Y/Y)
Total other income,
net
$27,075,000
(22.69%↑ Y/Y)
Collaboration Revenue
$10,000,000
Grant
$181,000
(-79.71%↓ Y/Y)
Loss from operations
-$117,269,000
(48.86%↑ Y/Y)
Total revenue
$10,181,000
(1041.37%↑ Y/Y)
Total operating
expenses
$127,450,000
(-44.64%↓ Y/Y)
Research and development
$67,152,000
(-3.92%↓ Y/Y)
Collaboration expense, net
$40,272,000
(-10.81%↓ Y/Y)
General and
administrative
$17,553,000
(-7.21%↓ Y/Y)
Acquired in-process
research and development
$2,473,000
(-97.43%↓ Y/Y)
Buy us a coffee
CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics AG (CRSP)